← 返回

细胞因子诱导的记忆样 NK 细胞:从基础到临床应用

英文原题:Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications.

查看英文原题

Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications.

PubMed 2022/05/04(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞是一类淋巴细胞,在抵御病毒感染和肿瘤细胞中发挥关键作用。尽管NK细胞被归类为固有淋巴样细胞(ILC),但在某些情况下它们表现出适应性和记忆样特征。后者可通过短暂刺激白细胞介素(IL)-12、IL-15和IL-18等方式实现。这些细胞因子诱导的记忆样(CIML)NK细胞类似于在髓系细胞中观察到的训练免疫。CIML NK细胞经历转录、表观遗传和代谢重编程,连同细胞表面受体和细胞毒性颗粒组分表达的变化,共同导致其在静息期后效应功能增强。

此外,这些记忆样NK细胞可长期持续存在,使其成为癌症免疫治疗的良好候选者。目前,多项临床试验正在测试CIML NK细胞输注以治疗肿瘤,主要为血液系统恶性肿瘤。在复发/难治性急性髓系白血病(AML)中,过继转移CIML NK细胞是安全的,并已观察到完全临床缓解。在本综述中,我们旨在总结关于NK细胞记忆样反应的产生和分子基础的最新知识,以及CIML NK细胞临床试验的最新结果。

展开英文摘要原文

Natural killer (NK) cells are lymphocytes with a key role in the defense against viral infections and tumor cells. Although NK cells are classified as innate lymphoid cells (ILCs), under certain circumstances they exhibit adaptive and memory-like features. The latter may be achieved, among others, by a brief stimulation with interleukin (IL)-12, IL-15 and IL-18.

These cytokine-induced memory-like (CIML) NK cells resemble the trained immunity observed in myeloid cells. CIML NK cells undergo transcriptional, epigenetic and metabolic reprogramming that, along with changes in the expression of cell surface receptors and components of cytotoxic granules, are responsible for their enhanced effector functions after a resting period.

In addition, these memory-like NK cells persist for a long time, which make them a good candidate for cancer immunotherapy. Currently, several clinical trials are testing CIML NK cells infusions to treat tumors, mostly hematological malignancies.

In relapse/refractory acute myeloid leukemia (AML), the adoptive transfer of CIML NK cells is safe and complete clinical remissions have been observed. In our review, we sought to summarize the current knowledge about the generation and molecular basis of NK cell memory-like responses and the up-to-date results from clinical trials with CIML NK cells.

论文信息

作者
Terrén I、Orrantia A、Astarloa-Pando G、Amarilla-Irusta A、Zenarruzabeitia O、Borrego F
单位
Immunopathology Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.Spain
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 35603208 · DOI 10.3389/fimmu.2022.884648